Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774567 | 1.00 | NR3C1 (0.72) | NR3C1PGRNR3C2 | |
| SCHEMBL3172915 | 0.95 | NR3C1 (0.72) | NR3C1PGRNR3C2 | |
| SCHEMBL14218593 | 0.94 | NR3C1 (0.71) | NR3C1PGRNR3C2 | |
| SCHEMBL3171678 | 0.94 | NR3C1 (0.71) | NR3C1PGRNR3C2 | |
| SCHEMBL1775353 | 0.94 | NR3C1 (0.69) | NR3C1PGRNR3C2 | |
| SCHEMBL3171691 | 0.94 | NR3C1 (0.70) | NR3C1PGRNR3C2 | |
| SCHEMBL3171414 | 0.93 | NR3C1 (0.70) | NR3C1PGRNR3C2 | |
| SCHEMBL14218568 | 0.93 | NR3C1 (0.70) | NR3C1PGRNR3C2 | |
| SCHEMBL1775742 | 0.93 | NR3C1 (0.73) | NR3C1PGRNR3C2 | |
| SCHEMBL1775810 | 0.93 | NR3C1 (0.73) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | claimed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | claimed |
| EP-2013185-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-01-14 | — | — | EP | claimed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | claimed |
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| EP-2013185-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265326-A1 | NOVEL COMPOUNDS | CCL11, MRGPRX2, LTB4R2 | NR3C1 190/4885PGR 1312/4885NR3C2 271/4885 |
| US-20090111866-A1 | Novel Compounds | CCL11, MRGPRX2, LTB4R2 | NR3C1 190/4885PGR 1312/4885NR3C2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.